Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patterns of care and outcome of CIC-rearranged sarcoma patients: A nationwide study of the French sarcoma group.
Brahmi M, Gaspar N, Gantzer J, Toulmonde M, Boudou-Rouquette P, Bompas E, Firmin N, Valentin T, Cancel M, Duffaud F, Bertucci F, Perrin C, Dufresne A, Marec-Bérard P, Jean-Denis M, Ray-Coquard I, Le Loarer F, Pierron G, Tirode F, Blay JY, Watson S. Brahmi M, et al. Cancer Med. 2023 Apr;12(7):7801-7807. doi: 10.1002/cam4.5539. Epub 2022 Dec 20. Cancer Med. 2023. PMID: 36537582 Free PMC article.
Erratum to: Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients.
Heidelberger V, Goldwasser F, Kramkimel N, Jouinot A, Huillard O, Boudou-Rouquette P, Chanal J, Arrondeau J, Franck N, Alexandre J, Blanchet B, Leroy K, Avril MF, Dupin N, Aractingi S. Heidelberger V, et al. Invest New Drugs. 2017 Aug;35(4):537. doi: 10.1007/s10637-017-0475-7. Invest New Drugs. 2017. PMID: 28597150 No abstract available.
Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study.
Boudou-Rouquette P, Arrondeau J, Gervais C, Durand JP, Fabre E, De Percin S, Villeminey CV, Piketty AC, Rassy N, Ulmann G, Damotte D, Mansuet-Lupo A, Giraud F, Alifano M, Wislez M, Alexandre J, Jouinot A, Goldwasser F. Boudou-Rouquette P, et al. EBioMedicine. 2021 Nov;73:103630. doi: 10.1016/j.ebiom.2021.103630. Epub 2021 Oct 20. EBioMedicine. 2021. PMID: 34688030 Free PMC article.
Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.
Tiako Meyo M, Jouinot A, Giroux-Leprieur E, Fabre E, Wislez M, Alifano M, Leroy K, Boudou-Rouquette P, Tlemsani C, Khoudour N, Arrondeau J, Thomas-Schoemann A, Blons H, Mansuet-Lupo A, Damotte D, Vidal M, Goldwasser F, Alexandre J, Blanchet B. Tiako Meyo M, et al. Cancers (Basel). 2020 Feb 18;12(2):473. doi: 10.3390/cancers12020473. Cancers (Basel). 2020. PMID: 32085544 Free PMC article.
Metastatic fractures of long limb bones.
Anract P, Biau D, Boudou-Rouquette P. Anract P, et al. Orthop Traumatol Surg Res. 2017 Feb;103(1S):S41-S51. doi: 10.1016/j.otsr.2016.11.001. Epub 2017 Jan 11. Orthop Traumatol Surg Res. 2017. PMID: 28089230 Free article. Review.
120 results